Document is current
Any future updates will be listed below
-
Authors
Weber, Katharina S.
Schlesinger, Sabrina
Goletzke, Janina
Straßburger, Klaus
Zaharia, Oana-Patricia
Trenkamp, Sandra
Wagner, Robert
Lieb, Wolfgang
Buyken, Anette E.
Roden, Michael
Herder, Christian
,
Roden, M.
Al-Hasani, H.
Belgardt, B.
Bönhof, G.
Geerling, G.
Guthoff, R.
Herder, C.
Icks, A.
Jandeleit-Dahm, K.
Kotzka, J.
Kuß, O.
Lammert, E.
Rathmann, W.
Schlesinger, S.
Schrauwen-Hinderling, V.
Szendroedi, J.
Trenkamp, S.
Wagner, R.
-
Funding
Funding for this research was provided by:
Universitätsklinikum Schleswig-Holstein - Campus Kiel
- License Information
-
More Information
Article History
Received: 17 October 2024
Accepted: 4 January 2025
First Online: 6 February 2025
Declarations
:
: The study protocol has been approved by the ethics board of Heinrich Heine University. The study is conducted according to the ethical standards as laid down in the 1964 Declaration of Helsinki. All participants gave written informed consent.
: Not applicable.
: A.E.B. is a member of the International Carbohydrate Quality Consortium (ICQC), a member of the Scientific committee of the transnational governance of the Nutri-Score system, a member of the Scientific Advisory Council for Agricultural Policy, Nutrition and Consumer Health Protection, Federal Ministry of Food and Agriculture Germany and a co-author of the popular cookbook “Nordisch abnehmen”. Her research is supported by grants from the German Research Foundation (BU 1807/3-2 & BU 1807/8-1), and the European Joint Programming Initiative “A Healthy Diet for a Healthy Life” and from the ERA-NET Cofund HDHL INTIMIC (GA No. 727565 of the EU Horizon 2020 Research and InnovationProgramme). M.R. received fees consulting, lecturing or serving on advisory boards from Astra Zeneca, Boehringer-Ingelheim, Echosens, Eli Lilly, Merck-MSD, Madrigal, Novo Nordisk, Madrigal and Target RWE and has performed investigator-initiated research with support from Boehringer-Ingelheim, Novo Nordisk and Nutricia/Danone to the DDZ. The research of M.R. is supported by grants from the German Research Foundation (DFG; RTG/GRK 2576), the European Community (HORIZON-HLTH-2022-STAYHLTH-02-01: Panel A) to the INTERCEPT-T2D consortium, BMG, MKW, BMBF and the Schmutzler-Stiftung. R.W. reports lecture fees from Novo Nordisk, Sanofi-Aventis, Boehringer-Ingelheim and Eli Lilly. He served on the advisory board for Akcea Therapeutics, Daiichi Sankyo, Eli Lilly and NovoNordisk. None of these aforementioned relationships/activities are related to the content of this manuscript. J.G., C.H., W.L., K.S.W., S.S., K.S., S.T., and O.P.Z. declare no competing interests.
